Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 35kWORD 19k
12 May 2022
E-000804/2022(ASW)
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: E-000804/2022

The Commission cannot comment on the specific pricing per dose, in view of contractual obligations of confidentiality.

Through advance purchase agreements with individual vaccine producers, the Commission secured the right to buy vaccines at a given price.

In return, the Commission financed a part of the upfront costs from the EUR 2.7 billion Emergency Support Instrument(1). This funding was considered a down payment on the vaccines that Member States purchase, responsible for the remaining costs.

The Commission has given conditional marketing authorisations to five COVID-19 vaccines. The European Medicines Agency (EMA) is assessing other five vaccines, four of which are under rolling review(2).

The speed during a rolling review depends on how quickly the company provides to EMA the required data on the vaccine’s safety, effectiveness and quality, including data on manufacturing.

On patents, the Commission is engaged in the discussion at the World Trade Organisation (WTO) on the role of intellectual property in enhancing global access to COVID-19 vaccines.

The Commission had discussions in a quadrilateral format with South Africa, India and the United States, facilitated by the WTO Director-General, resulting in a compromise that needs to be confirmed for further proceeding by governments of the quad (the EU has already given its green light) and then agreed by the broader WTO Membership.

The outcome, if agreed, would allow Members to rapidly authorise a company to manufacture and export COVID-19 vaccines and ensure that countries with no or insufficient manufacturing capacity do not face obstacles or legal uncertainty to import these vaccines.

(1)https://ec.europa.eu/info/live-work-travel-eu/coronavirus-response/emergency-support-instrument_en
(2)https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines
Last updated: 17 May 2022Legal notice - Privacy policy